Madrigal Pharmaceuticals Announces NDA Acceptance And Priority Review Of New Drug Application For Resmetirom For Treatment Of NASH With Liver Fibrosis
Portfolio Pulse from Bill Haddad
Madrigal Pharmaceuticals has announced that its New Drug Application (NDA) for Resmetirom, a treatment for NASH with liver fibrosis, has been accepted and given priority review.
September 13, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Madrigal Pharmaceuticals' NDA for Resmetirom has been accepted and given priority review, which could potentially expedite the drug's approval process.
The acceptance and priority review of the NDA for Resmetirom by Madrigal Pharmaceuticals is a positive development for the company. This could potentially expedite the drug's approval process, leading to earlier sales and revenue generation. This news is highly relevant and important for investors in MDGL, as it directly impacts the company's product pipeline and future revenue potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100